The Effects of Pyrrolo[1,2-b][1,2,5]Benzothiadiazepines in MEC1 Cells
ABSTRACT Chronic Lymphocytic Leukemia (CLL) is the most common adult leukemia and is currently incurable. To expand the therapeutic armamentarium, we investigated antitumor activity of pyrrolo[1,2‐b][1,2,5]benzothiadiazepine (PBTDs) in MEC1 cells. We found that PBTD (RS2778) treatment enhanced the a...
Saved in:
Published in: | Journal of cellular biochemistry Vol. 116; no. 2; pp. 339 - 349 |
---|---|
Main Authors: | , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
Blackwell Publishing Ltd
01-02-2015
Wiley Subscription Services, Inc |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | ABSTRACT
Chronic Lymphocytic Leukemia (CLL) is the most common adult leukemia and is currently incurable. To expand the therapeutic armamentarium, we investigated antitumor activity of pyrrolo[1,2‐b][1,2,5]benzothiadiazepine (PBTDs) in MEC1 cells. We found that PBTD (RS2778) treatment enhanced the activation of pro‐apoptotic members, such as caspase‐9, 3, poly (ADP‐ribose) polymerase (PARP), and bax, but suppressed the activation of anti‐apoptotic molecule BCL‐2 in these cells. Furthermore, PBTD (RS2778)‐induced autophagic cell death was verified by LC3‐II conversion, and upregulation of Beclin‐1 and ATG5. In addition, such compound impeded hyper phosphorylation of AKT as were determined by Western blot. In summary, PBTD (RS2778) inhibited viability and induced multiple cellular events including apoptosis, autophagic cell death, in human MEC1 cells. This distinct activity of PBTD (RS2778) against these cells suggests potential for PBTDs as a therapeutic agent for treatment of CLL. J. Cell. Biochem. 116: 339–349, 2015. © 2014 Wiley Periodicals, Inc. |
---|---|
Bibliography: | ArticleID:JCB24977 ark:/67375/WNG-GS5XRV1H-C istex:8A6F22BBE7FF93370E9F183EB4AC1EA17EB0955A ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0730-2312 1097-4644 |
DOI: | 10.1002/jcb.24977 |